Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:NKTXNASDAQ:NMRANASDAQ:PULMNASDAQ:RAPT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNKTXNkarta$1.90+3.8%$1.82$1.31▼$8.23$134.82M0.811.06 million shs615,328 shsNMRANeumora Therapeutics$1.02+25.9%$0.72$0.61▼$17.19$164.98M2.731.52 million shs1.83 million shsPULMPulmatrix$8.89-0.1%$6.59$1.78▼$10.40$32.45M1.45133,471 shs48,433 shsRAPTRAPT Therapeutics$1.17+14.7%$0.92$0.71▼$4.01$154.78M-0.041.29 million shs953,506 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNKTXNkarta+3.83%+8.26%+1.60%+3.26%-72.86%NMRANeumora Therapeutics+25.91%+43.80%+57.41%-31.54%-89.79%PULMPulmatrix-0.11%+3.86%+42.83%+24.16%+351.27%RAPTRAPT Therapeutics+14.71%+30.96%+46.18%+3.54%-71.94%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationNKTXNkarta2.3037 of 5 stars3.61.00.00.03.31.70.6NMRANeumora Therapeutics2.0188 of 5 stars3.10.00.00.02.62.51.3PULMPulmatrix0.2296 of 5 stars0.05.00.00.00.00.00.0RAPTRAPT Therapeutics3.8406 of 5 stars3.21.00.04.22.41.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNKTXNkarta 3.13Buy$14.67671.93% UpsideNMRANeumora Therapeutics 2.22Hold$9.29810.36% UpsidePULMPulmatrix 0.00N/AN/AN/ARAPTRAPT Therapeutics 2.33Hold$3.00156.41% UpsideCurrent Analyst Ratings BreakdownLatest PULM, RAPT, NKTX, and NMRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2025RAPTRAPT TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$2.00 ➝ $1.005/22/2025RAPTRAPT TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$6.005/15/2025NKTXNkartaWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform5/15/2025NKTXNkartaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $10.005/13/2025NMRANeumora TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.004/10/2025NMRANeumora TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.004/9/2025NKTXNkartaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $11.004/2/2025NMRANeumora TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Underperform$7.00 ➝ $1.003/27/2025NKTXNkartaStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $14.003/27/2025NKTXNkartaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.00 ➝ $18.003/27/2025NKTXNkartaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $11.00(Data available from 6/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNKTXNkartaN/AN/AN/AN/A$5.56 per shareN/ANMRANeumora TherapeuticsN/AN/AN/AN/A$3.07 per shareN/APULMPulmatrix$1.92M16.89N/AN/A$4.93 per share1.80RAPTRAPT Therapeutics$1.53M101.16N/AN/A$4.27 per share0.27Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNKTXNkarta-$117.50M-$1.51N/AN/AN/AN/A-27.13%-21.67%8/12/2025 (Estimated)NMRANeumora Therapeutics-$235.93M-$1.61N/AN/AN/AN/A-73.63%-68.97%8/5/2025 (Estimated)PULMPulmatrix-$14.12M-$3.34N/A∞N/A-96.51%-45.97%-30.72%8/11/2025 (Estimated)RAPTRAPT Therapeutics-$116.80M-$2.40N/AN/AN/AN/A-89.10%-76.13%8/14/2025 (Estimated)Latest PULM, RAPT, NKTX, and NMRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025PULMPulmatrixN/A-$0.50N/A-$0.50N/AN/A5/14/2025Q1 2025NKTXNkarta-$0.44-$0.43+$0.01-$0.43N/AN/A5/12/2025Q1 2025NMRANeumora Therapeutics-$0.40-$0.42-$0.02-$0.42N/AN/A5/8/2025Q1 2025RAPTRAPT Therapeutics-$0.31-$0.08+$0.23-$0.08N/AN/A3/26/2025Q4 2024NKTXNkarta-$0.41-$0.35+$0.06-$0.35N/AN/A3/21/2025Q4 2024PULMPulmatrixN/A-$0.54N/A-$0.54N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthNKTXNkartaN/AN/AN/AN/AN/ANMRANeumora TherapeuticsN/AN/AN/AN/AN/APULMPulmatrixN/AN/AN/AN/AN/ARAPTRAPT TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNKTXNkartaN/A12.9112.91NMRANeumora TherapeuticsN/A10.9810.98PULMPulmatrixN/A19.4019.40RAPTRAPT TherapeuticsN/A9.909.90Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNKTXNkarta80.54%NMRANeumora Therapeutics47.65%PULMPulmatrix11.84%RAPTRAPT Therapeutics99.09%Insider OwnershipCompanyInsider OwnershipNKTXNkarta8.70%NMRANeumora Therapeutics26.80%PULMPulmatrix0.62%RAPTRAPT Therapeutics2.36%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNKTXNkarta14070.96 million64.43 millionOptionableNMRANeumora Therapeutics108161.75 million118.91 millionOptionablePULMPulmatrix203.65 million3.63 millionNot OptionableRAPTRAPT Therapeutics80132.29 million32.65 millionOptionablePULM, RAPT, NKTX, and NMRA HeadlinesRecent News About These CompaniesRapt Therapeutics Get A Bullish Recommendation On ‘Significant Opportunity’ For Allergy Drug Candidate: Retail Worries About Cash PositionJune 6 at 2:59 AM | msn.comRAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives $3.00 Consensus PT from AnalystsJune 6 at 2:31 AM | americanbankingnews.comRapt Therapeutics cuts staff for 2nd time in under a year, continuing fallout from FDA holdJune 4 at 4:51 PM | fiercebiotech.comRAPT Therapeutics to Participate in Upcoming Investor ConferencesJune 4 at 4:05 PM | globenewswire.comRAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Consensus Recommendation of "Hold" from BrokeragesJune 3, 2025 | marketbeat.comShort Interest in RAPT Therapeutics, Inc. (NASDAQ:RAPT) Rises By 39.9%June 2, 2025 | marketbeat.comWhat is HC Wainwright's Forecast for RAPT Q2 Earnings?May 27, 2025 | marketbeat.com12 Health Care Stocks Moving In Friday's Intraday SessionMay 25, 2025 | benzinga.comRAPT Therapeutics (NASDAQ:RAPT) Upgraded to "Hold" at Wall Street ZenMay 24, 2025 | marketbeat.comUBS Group Issues Pessimistic Forecast for RAPT Therapeutics (NASDAQ:RAPT) Stock PriceMay 24, 2025 | marketbeat.comRAPT Therapeutics (NASDAQ:RAPT) Earns Buy Rating from HC WainwrightMay 24, 2025 | marketbeat.com11,764,000 Shares in RAPT Therapeutics, Inc. (NASDAQ:RAPT) Acquired by RTW Investments LPMay 18, 2025 | marketbeat.comRapt Therapeutics (RAPT) Upgraded to Buy: Here's What You Should KnowMay 16, 2025 | zacks.com13,135,260 Shares in RAPT Therapeutics, Inc. (NASDAQ:RAPT) Purchased by Orbimed Advisors LLCMay 15, 2025 | marketbeat.comRAPT Therapeutics, Inc. (NASDAQ:RAPT) Given Average Rating of "Hold" by AnalystsMay 11, 2025 | marketbeat.comDeep Track Capital LP Invests $9.50 Million in RAPT Therapeutics, Inc. (NASDAQ:RAPT)May 9, 2025 | marketbeat.comColumn Group LLC Lowers Stock Holdings in RAPT Therapeutics, Inc. (NASDAQ:RAPT)May 9, 2025 | marketbeat.comRAPT Therapeutics Reports First Quarter 2025 Financial ResultsMay 8, 2025 | globenewswire.comWhy RAPT Therapeutics, Inc.’s (RAPT) Stock Is Down 5.55%May 8, 2025 | aaii.comIs RAPT Therapeutics (NASDAQ:RAPT) In A Good Position To Invest In Growth?April 18, 2025 | finance.yahoo.comRapt Therapeutics appoints Jessica Savage as VP, clinical developmentApril 17, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePULM, RAPT, NKTX, and NMRA Company DescriptionsNkarta NASDAQ:NKTX$1.90 +0.07 (+3.83%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$1.92 +0.02 (+1.05%) As of 06/6/2025 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.Neumora Therapeutics NASDAQ:NMRA$1.02 +0.21 (+25.91%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$1.04 +0.02 (+2.45%) As of 06/6/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.Pulmatrix NASDAQ:PULM$8.89 -0.01 (-0.11%) Closing price 06/6/2025 03:57 PM EasternExtended Trading$8.91 +0.02 (+0.22%) As of 06/6/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.RAPT Therapeutics NASDAQ:RAPT$1.17 +0.15 (+14.71%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$1.15 -0.02 (-1.71%) As of 06/6/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/02 - 06/06 This Banking Giant Just Got a $90 Price Target Upgrade Broadcom Slides on Solid Earnings, AI Outlook Still Strong The Market’s Silent Warning: What Bonds and Gold Reveal MongoDB Affirms Outlook and Accelerates Stock Price Reversal Are NVIDIA's Ethernet Wins Signs of Hope or Horror for Arista? AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? Why Visa's Innovation Engine Keeps It a Top Portfolio Pick Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
